HOOKIPA (HOOK) Form 144/A: Insider Sale 25,172 Shares on 08/19/2025

HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ.

Rhea-AI Filing Summary

HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ. The filing lists an aggregate market value of $20,155 for the shares and shows 9,789,622 shares outstanding.

The securities were acquired as restricted stock units on 07/22/2024 (amount: 54,347) and the notice states the intended payment is compensation. The filing also discloses a recent sale on 07/23/2025 of 29,176 shares for $26,911. The signer represents no undisclosed material adverse information about the issuer.

Positive

• Transparent filing of planned insider sale with broker, date, and amount disclosed
• Includes recent sale activity (29,176 shares on 07/23/2025 for $26,911), improving market transparency
• Acquisition method disclosed (Restricted Stock Units dated 07/22/2024) and payment nature (compensation)

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; size is small relative to shares outstanding and unlikely to be material to valuation.

The Form 144/A documents a planned sale of 25,172 common shares by a person who acquired 54,347 RSUs in July 2024. With 9.79 million shares outstanding, the proposed sale represents a small fraction of equity (<0.26%). The filing provides transaction timing, broker identity, and recent past sales, which supports market transparency. There is no earnings or operational data here to reassess company fundamentals.

Compliance/Risk Analyst

TL;DR: Disclosure complies with Rule 144 reporting elements; includes the required representations and broker details.

The submission identifies the broker (Maxim Group), sale date, acquisition method (RSUs), and past three-month sale activity, satisfying key Form 144 requirements. The signer affirms absence of undisclosed material adverse information, and the filing flags the transaction as compensation-related. From a compliance perspective, the document appears complete for a Rule 144 notice; it does not raise immediate regulatory red flags based on the provided fields.

FAQ

What shares does HOOKIPA (HOOK) plan to sell under this Form 144/A?

The filer plans to sell 25,172 shares of HOOKIPA common stock on 08/19/2025 via Maxim Group on the NASDAQ.

How many HOOKIPA shares are outstanding according to the filing?

The filing reports 9,789,622 shares outstanding.

When were the securities being sold originally acquired?

The securities were acquired as Restricted Stock Units on 07/22/2024, totaling 54,347 units.

Did the filer sell any HOOKIPA shares in the past three months?

Yes. The filer sold 29,176 shares on 07/23/2025 for gross proceeds of $26,911.

What is the aggregate market value of the proposed sale?

The aggregate market value reported for the 25,172 shares is $20,155.

Does the filing state whether undisclosed material information exists?

The signer represents by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/27/2025 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001876563
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001970051-25-000025
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	HOOKIPA Pharma Inc.
SEC File Number	001-38869
Address of Issuer	350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 NEW YORK NEW YORK 10118
Phone	0114318906360
Name of Person for Whose Account the Securities are To Be Sold	Peters Malte
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group 300 Park Ave 16th Floor New York NY 10022	25172	20155.00	9789622	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/22/2024	Restricted Stock Units	Issuer			54347	08/19/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Peters Malte 350 FIFTH AVENUE, 72ND FLOOR SUITE 7240 NEW YORK NY 10118	Common Stock	07/23/2025	29176	26911.00

144/A: Remarks and Signature

Remarks	An amended 144 was filed due to missing a Sell to Cover of 29,176 shares on 07/23/25
Date of Notice	08/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Dominick Iadicicco, as a duly authorized representative of Maxim Group LLC., as attorney-in-fact for Malte Peter
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)